Spyre Therapeutics, Inc. (NASDAQ: SYRE) announced that it has finished enrolling patients for the rheumatoid arthritis (RA) sub‑study of its SKYWAY basket trial, a pivotal phase‑2 program that evaluates the long‑acting anti‑TL1A antibody SPY072 across multiple inflammatory diseases.
The RA sub‑study now has a full cohort of patients, allowing the company to begin interim data collection and move toward a topline readout that is now expected in the third quarter of 2026—an acceleration from the previously anticipated fourth‑quarter timeline. While the exact enrollment number was not disclosed, management noted that enrollment “has exceeded our expectations,” underscoring strong investigator enthusiasm and a robust unmet need in RA.
Joshua Friedman, M.D., Ph.D., Senior Vice President of Clinical Development and SKYWAY study lead, said, “Enrollment in the RA sub‑study of SKYWAY has exceeded our expectations and reflects both substantial unmet need as well as investigator enthusiasm for the potential of a long‑acting anti‑TL1A antibody. We look forward to delivering the first proof‑of‑concept data for this mechanism in rheumatic disease in the third quarter, with the potential to advance to pivotal trials next year.” CEO Cameron Turtle added that the company’s goal is to “identify multiple products that leapfrog today’s standard of care and provide substantially improved therapies for patients suffering from severe autoimmune diseases.”
Spyre’s cash and securities totaled $756.5 million as of December 31 2025, giving the company a runway into the second half of 2028. The strong balance sheet supports continued investment in the SKYWAY program and other pipeline assets, positioning the company to fund the next phases of development without immediate financing needs.
Analysts at Guggenheim reiterated Spyre as a top pick for 2026 following the announcement, citing the accelerated timeline and robust enrollment as key drivers of investor confidence. The company’s focus on a long‑acting antibody that could be dosed quarterly or twice‑yearly addresses a significant market opportunity in post‑TNF rheumatoid arthritis, estimated at more than $10 billion, and could provide a competitive advantage over existing therapies.
The completion of enrollment and the earlier‑than‑expected readout signal that Spyre’s platform is executing efficiently and that its lead candidate, SPY072, is progressing toward pivotal trials. If the third‑quarter data confirm efficacy and safety, the company could move to a pivotal study in 2027, potentially accelerating regulatory submissions and market entry for a therapy that could transform the treatment landscape for RA and other inflammatory diseases.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.